Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019024310) PRAMIPEXOLE HYDROCHLORIDE SUSTAINED RELEASE PREPARATION AND PREPARATION METHOD THEREFOR.
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/024310 International Application No.: PCT/CN2017/110351
Publication Date: 07.02.2019 International Filing Date: 10.11.2017
IPC:
A61K 9/52 (2006.01) ,A61K 9/50 (2006.01) ,A61K 47/38 (2006.01) ,A61K 47/32 (2006.01) ,A61K 31/428 (2006.01) ,A61P 25/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
52
Sustained or differential release type
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
48
Preparations in capsules, e.g. of gelatin, of chocolate
50
Microcapsules
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
36
Polysaccharides; Derivatives thereof
38
Cellulose; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
30
Macromolecular compounds
32
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425
Thiazoles
428
condensed with carbocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
Applicants:
深圳翰宇药业股份有限公司 HYBIO PHARMACEUTICAL CO., LTD. [CN/CN]; 中国广东省深圳市 南山区高新技术工业园中区翰宇生物医药园办公大楼四层 4th Floor of Office Building Hybio Medicine Park, Shenzhen Hi-Tech Industrial Park, Nanshan District Shenzhen, Guangdong 518057, CN
Inventors:
林浩文 LIN, Haowen; CN
颜携国 YAN, Xieguo; CN
陶安进 TAO, Anjin; CN
袁建成 YUAN, Jiancheng; CN
Agent:
深圳市深佳知识产权代理事务所(普通合伙) SHENPAT INTELLECTUAL PROPERTY AGENCY; 中国广东省深圳市 国贸大厦15楼西座1521室 Room 1521 West Block, Guomao Building Shenzhen, Guangdong 518014, CN
Priority Data:
201710642262.131.07.2017CN
Title (EN) PRAMIPEXOLE HYDROCHLORIDE SUSTAINED RELEASE PREPARATION AND PREPARATION METHOD THEREFOR.
(FR) PRÉPARATION À LIBÉRATION PROLONGÉE DE CHLORHYDRATE DE PRAMIPEXOLE ET SON PROCÉDÉ DE PRÉPARATION
(ZH) 一种盐酸普拉克索缓释制剂及其制备方法
Abstract:
(EN) A pramipexole hydrochloride sustained release preparation and a preparation method therefor. The sustained release preparation comprises first sustained-release pellets and third sustained-release pellets. The first sustained-release pellets comprise pramipexole hydrochloride first medicated pellets, a first coating, and a second coating. The third sustained-release pellets comprise pramipexole hydrochloride third medicated pellets and a third coating. The content ratio of pramipexole hydrochloride in the first sustained-release pellets to pramipexole hydrochloride in the third sustained-release pellets is 4:1. The burst effect of pramipexole hydrochloride under acidic conditions can be avoided.
(FR) L'invention porte sur une préparation à libération prolongée de chlorhydrate de Pramipexole et sur son procédé de préparation. La préparation à libération prolongée comprend des premières pastilles à libération prolongée et des troisièmes pastilles à libération prolongée. Les premières pastilles à libération prolongée comprennent des premières pastilles médicamenteuses de chlorhydrate de Pramipexole, un premier enrobage et un deuxième enrobage. Les troisièmes pastilles à libération prolongée comprennent des troisièmes pastilles médicamenteuses de chlorhydrate de Pramipexole et un troisième enrobage. Le rapport de la teneur en chlorhydrate de Pramipexole dans les premières pastilles à libération prolongée au chlorhydrate de Pramipexole dans les troisièmes pastilles à libération prolongée est de 4:1. L'effet de décharge de chlorhydrate de Pramipexole dans des conditions acides peut être évité.
(ZH) 一种盐酸普拉克索缓释制剂及其制备方法,缓释制剂包含第一缓释微丸和第三缓释微丸,所述第一缓释微丸包含盐酸普拉克索第一含药微丸、第一包衣和第二包衣,所述第三缓释微丸包含盐酸普拉克索第三含药微丸和第三包衣,所述第一缓释微丸中的盐酸普拉克索与第三缓释微丸中的盐酸普拉克索的含量比为4:1。可避免盐酸普拉克索在酸性条件下的突释效应。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)